PharmAthene, Inc.  

(Public, NYSEMKT:PIP)   Watch this stock  
Find more results for NYSEAMEX:PIP
0.00 (0.00%)
May 22 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.61 - 1.65
52 week 1.19 - 2.59
Open 1.63
Vol / Avg. 54,627.00/70,053.00
Mkt cap 104.62M
P/E     -
Div/yield     -
EPS -0.11
Shares 63.79M
Beta 1.89
Inst. own 41%
Aug 5, 2015
Q2 2015 PharmAthene Inc Earnings Release (Estimated) Add to calendar
May 7, 2015
Q1 2015 PharmAthene Inc Earnings Release
Mar 9, 2015
Full Year 2014 PharmAthene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 20.70% -97.70%
Operating margin 16.43% -100.01%
EBITD margin - -98.54%
Return on average assets 24.74% -50.90%
Return on average equity 30.65% -77.75%
Employees 35 -
CDP Score - -


1 Park Pl Ste 450
ANNAPOLIS, MD 21401-3481
United States - Map
+1-410-2692600 (Phone)
+1-410-2692601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


PharmAthene, Inc. is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical threats. The Company’s biodefense portfolio of product candidates include SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. SparVax is a second generation, rPA anthrax vaccine designed to protect against inhalational anthrax, the most lethal form of B. anthracis infection in humans. Valortim is a fully human monoclonal antibody designed to protect against and treat human inhalational anthrax, as both post-exposure prophylaxis and post-exposure therapy.

Officers and directors

Mitchel B. Sayare Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
John M. Gill President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Philip MacNeill Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 62
Bio & Compensation  - Reuters
Jeffrey M. Jones Ph.D. Chief Operating Officer, Vice President
Age: 43
Bio & Compensation  - Reuters
Eric I. Richman Director
Age: 54
Bio & Compensation  - Reuters
Jeffrey W. Runge M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Derace L. Schaffer M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven St. Peter M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters